Krilogy Financial LLC Exelixis, Inc. Transaction History

Krilogy Financial LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 14, 2019	SELL	$13.65 - $21.8 $2,730 - $4,360	-200 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$15.87 - $22.4 $3,174 - $4,480	200 New	200 $4,000
Q2 2018 Aug 15, 2018	SELL	$18.56 - $22.45 $3,711 - $4,490	-200 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$22.15 - $31.89 $8,860 - $12,756	-400 Reduced 66.67%	200 $4,000
Q4 2017 Feb 14, 2018	BUY	$24.23 - $30.93 $7,269 - $9,279	300 Added 100.0%	600 $18,000
Q3 2017 Nov 15, 2017	SELL	$23.35 - $29.24 $18,680 - $23,392	-800 Reduced 72.73%	300 $7,000
Q2 2017 Aug 15, 2017	BUY	N/A	1,100	1,100 $27,000

501

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.5B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Krilogy Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Krilogy Financial LLC with notifications on news.